Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Market Closed 09-25 16:00:00 EDT

33.30

-0.70

-2.06%

盘后33.30

+0.000.00%

19:50 EDT

High34.22	Low33.17	Vol2.35M
Open34.00	D1 Closing34.00	Amplitude3.07%
Mkt Cap6.87B	Tradable Cap2.98B	Total Shares206.40M
T/O78.46M	T/O Rate2.62%	Tradable Shares89.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":33.3,"timestamp":1790366400000,"preClose":34,"halted":0,"volume":2350081,"hourTrading":{"tag":"盘后","latestPrice":33.3,"preClose":33.3,"latestTime":"19:50 EDT","volume":547228,"amount":18222658.56,"timestamp":1790380202921,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02058823529411773,"floatShares":89566827,"shares":206402338,"eps":-2.817767,"marketStatus":"Market Closed","change":-0.7,"latestTime":"09-25 16:00:00 EDT","open":34,"high":34.215,"low":33.17,"amount":78464469.176785,"amplitude":0.030735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.817767,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":34,"preHourTrading":{"tag":"盘前","latestPrice":34.06,"preClose":34,"latestTime":"09:29 EDT","volume":1544,"amount":53336.210832000004,"timestamp":1790342999999,"change":0.06,"changeRate":0.001765,"amplitude":0.052353},"postHourTrading":{"tag":"盘后","latestPrice":33.3,"preClose":33.3,"latestTime":"19:50 EDT","volume":547228,"amount":18222658.56,"timestamp":1790380202921,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.034081723766966,"impliedVol":0.6678,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2670474558","title":"Immunovant (IMVT) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2670474558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670474558?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:35","pubTimestamp":1790433320,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant, with a price target of $53.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256471","title":"Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670256471?lang=en_us&edition=fundamental","pubTime":"2026-09-26 21:05","pubTimestamp":1790427914,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Hold rating on Immunovant, with a price target of $37.00. The company’s sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-reaffirms-their-hold-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669702438","title":"Immunovant Down over 7%, on Pace for Largest Percent Decrease Since July 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669702438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669702438?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:52","pubTimestamp":1790185920,"startTime":"0","endTime":"0","summary":"Immunovant Inc.  is currently at $34.60, down $2.70 or 7.23%--Would be lowest close since June 16, 2026, when it closed at $33.61--On pace for largest percent decrease since July 25, 2025, when it fell 7.48%--Snaps a two day winning streak--Down 15.25% month-to-date; on pace for worst month since March 2025, when it fell 17.04%--Up 36.09% year-to-date--Down 34.37% from its all-time closing high of $52.71 on Nov. 17, 2020--Up 123.77% from 52 weeks ago , when it closed at $15.46--Down 23.05% from its 52-week closing high of $44.96 on Aug. 19, 2026--Up 123.77% from its 52-week closing low of $15.46 on Sept. 24, 2025--Traded as low as $33.60; lowest intraday level since June 16, 2026, when it hit $32.86--Down 9.9% at today's intraday low; largest intraday percent decrease since July 25, 2025, when it fell as much as 16.43%All data as of 1:49:41 PM ETSource: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438224","title":"Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438224","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438224?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:45","pubTimestamp":1790185500,"startTime":"0","endTime":"0","summary":"Immunovant shares were on track for their worst session in over a year after the biotech said it was halting development of its experimental autoimmune drug in one indication following a trial miss.Im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBI","BK4581","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438452","title":"Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438452?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:30","pubTimestamp":1790184615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunovant (IMVT) and Oruka Therapeutics (ORKA) with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunovant-imvt-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0889565916.HKD","LU0320765992.SGD","LABU","HCSG","ORKA","LU0029874061.USD","BK4581","IMVT","XBI","BK4585","LU0128526141.USD","XLV","BK4137","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810804","title":"Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810804","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669810804?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:19","pubTimestamp":1790173140,"startTime":"0","endTime":"0","summary":"Immunovant said it saw negative topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 imeroprubart for the treatment of cutaneous lupus erythematosus.The company said the study didn't achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12.Immunovant said numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.The company said it will still focus on advancing the clinical development of IMVT-1402 across multiple autoimmune diseases, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4588","BK4581","IMVT","BK4585","BK4137","ROIV","HCSG","IBB","BK4139","PTH","LU0029874061.USD","XBI","XLV","LU0128526141.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","BK4170","BK4517","BK4566","ROIV","IMVT","BK4602","IONL","IONX","BK4591","LU1670628061.USD","WQTM","CARX","LU0300736062.USD","LU1366192091.USD","WNDR","BK4007","IONQ","CART","BK4585","IONZ","BK4139","LU0266013472.USD","BK4142","CQTM","PTH","LU1670627923.USD","BHP","QTUP","BK4588","IOYY","COAL","SLX","BK4113","RCL","BK4168","LU0300736492.USD","IONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","IMVT","BK4007","BK4139","BK4588","BK4585","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669883024","title":"Roivant announces trial of IMVT-1402 did not reach statistical significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2669883024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669883024?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:10","pubTimestamp":1790161851,"startTime":"0","endTime":"0","summary":"Roivant announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus er...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-announces-trial-of-imvt-1402-did-not-reach-statistical-significance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-announces-trial-of-imvt-1402-did-not-reach-statistical-significance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IMVT","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810064","title":"Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669810064?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669618100","title":"Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2669618100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669618100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669210061","title":"Immunovant, - to Stop Development of Imvt-1402 in Cle","url":"https://stock-news.laohu8.com/highlight/detail?id=2669210061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669210061?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7BQLZP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669881004","title":"Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669881004","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669881004?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161200,"startTime":"0","endTime":"0","summary":"Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367346/0/en/immunovant-announces-topline-results-from-proof-of-concept-study-of-imvt-1402-in-cutaneous-lupus-erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150016","title":"Analysts’ Top Healthcare Picks: LeonaBio (LONA), Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150016?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988431,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LeonaBio (LONA), Immunovant (IMVT) and Edwards Lifes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-leonabio-lona-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-leonabio-lona-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","BK4588","LABU","BK4139","XLV","LONA","BK4585","BK4581","HCSG","BK4007","BK4137","IMVT","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664049898","title":"Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2664049898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664049898?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:06","pubTimestamp":1788469582,"startTime":"0","endTime":"0","summary":"Immunovant holds annual stockholder meeting with 96% shares representedImmunovant held its annual shareholder meeting on Sept. 2, 2026.Shareholders backed the selection of Ernst & Young as independent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL364hlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4585","IMVT","BK4588","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125867","title":"Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125867","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125867?lang=en_us&edition=fundamental","pubTime":"2026-09-02 09:01","pubTimestamp":1788310876,"startTime":"0","endTime":"0","summary":"Roivant Sciences President, Immunovant CEO Eric Venker disposes of common shares worth $7.15 millionRoivant Sciences President and Immunovant CEO Eric Venker cut his stake to 1,599,154 common shares o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1wcvb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","BK4585","BK4007","BK4588","ROIV","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013728","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013728","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013728?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:29","pubTimestamp":1787948961,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905Immunovant director Atul Pande exercised stock options for 1,500 shares at $8.43 on Aug. 28, 2026.He sold 1,500 shares at $4","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLRTwYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4588","IMVT","BK4585","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662208957","title":"Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662208957","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662208957?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:16","pubTimestamp":1787591795,"startTime":"0","endTime":"0","summary":"Immunovant  has broad diversification with encouraging updates but faces balanced risk/reward profile after its stock's recent rally, UBS said in a note email Monday.The company's recent updates have moved UBS analysts to factor in more potential disease indications for the drug candidate INVT-1402, according to the note. The analysts updated their forecast for 2035 revenue to $3.2 billion from $1.9 billion previously, taking into account difficult-to-treat rheumatoid arthritis, as well as upcoming datasets such as cutaneous lupus erythematosus and Sjogren's disease.The company's stock price recently rose following positive clinical data in difficult-to-treat rheumatoid arthritis, which could have a favorable readthrough to other indications, the analysts said.However, the analysts said they remain \"on the sidelines\" until the phase 2 rheumatoid arthritis trial results, expected in H2, which may be mixed, but potentially could lead to clearer positive catalysts in 2027.Clinical trial r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661744472","title":"UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661744472","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661744472?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:09","pubTimestamp":1787580587,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has an average rating of buy and mean price target of $46.77, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0988},{"period":"1month","weight":-0.2413},{"period":"3month","weight":-0.1429},{"period":"6month","weight":0.3887},{"period":"1year","weight":1.1251},{"period":"ytd","weight":0.31}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.035685},{"month":8,"riseRate":0.625,"avgChangeRate":0.07742},{"month":9,"riseRate":0.75,"avgChangeRate":0.08269},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction